Avenue Therapeutics Inc. Stock
Your prediction
Avenue Therapeutics Inc. Stock
Our community identified positive and negative aspects for Avenue Therapeutics Inc. stock for the coming years. 3 users see the criterium "Company culture" as a plus for the Avenue Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Avenue Therapeutics Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Avenue Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Avenue Therapeutics Inc. | - | - | - | - | - | - | - |
| Pacira Pharmaceuticals | 0.000% | 1.000% | 6.878% | 15.429% | 9.189% | -53.881% | -59.274% |
| Rockwell Medical Inc. | 2.130% | 1.114% | -4.273% | -57.554% | -57.217% | -18.632% | -91.569% |
| Twist Bioscience Corp | -0.750% | 0.653% | 1.167% | -42.091% | -39.318% | 4.855% | -73.821% |
Comments
Avenue Therapeutics, Inc. (NASDAQ: ATXI) is now covered by analysts at Maxim Group. They set a "buy" rating and a $0.75 price target on the stock.
Show more
Ratings data for ATXI provided by MarketBeat
Avenue Therapeutics, Inc. (NASDAQ: ATXI) is now covered by analysts at Aegis. They set a "buy" rating and a $32.00 price target on the stock.
Show more
Ratings data for ATXI provided by MarketBeat
